{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:48:42Z","timestamp":1788281322059,"version":"build-2803163510"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Reprod. Health"],"abstract":"<jats:p>Compounded bioidentical hormone therapy (cBHT) for menopausal symptoms maintains popularity in western countries despite the availability of hormone products in different formulations and dosages produced by pharmaceutical companies with federal oversight. Akin to many populist therapeutic trends in the history of medicine, cBHT advocates tend to capitalize on consumer fears about existing FDA-approved hormone treatments. Unsubstantiated, exaggerated, or outright false claims are commonplace in promoting cBHT. Given these elements, the basic elements of pharmaceutical messianism continue to drive the cBHT movement.<\/jats:p>","DOI":"10.3389\/frph.2024.1378644","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T04:50:44Z","timestamp":1709182244000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Fear, misinformation, and pharmaceutical messianism in the promotion of compounded bioidentical hormone therapy"],"prefix":"10.3389","volume":"6","author":[{"given":"Robert P.","family":"Kauffman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"MacLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay A.","family":"Courtney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D.","family":"Vineyard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s11606-013-2604-0","article-title":"Content analysis of false and misleading claims in television advertising for prescription and nonprescription drugs","volume":"29","author":"Faerber","year":"2014","journal-title":"J Gen Intern Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.26355\/eurrev_202207_29205","article-title":"Over-the-counter (OTC) drug advertising: informative or harmful? - analysis based on polish research","volume":"26","author":"Radli\u0144ska","year":"2022","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.4140\/TCP.n.2021.489","article-title":"Online promotion of \u201cbrain health\u201d supplements","volume":"36","author":"Block","year":"2021","journal-title":"Sr Care Pharm"},{"key":"B4","year":""},{"key":"B5","year":""},{"key":"B6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/andr.307","article-title":"Designer steroids\u2013over-the-counter supplments and their androgenic component: review of an increasing problem","volume":"3","author":"Rahnema","year":"2015","journal-title":"Andrology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1097\/GME.0000000000002200","article-title":"The 2023 nonhormone therapy position statement of the North American menopause society","volume":"30","year":"2023","journal-title":"Menopause"},{"key":"B8","doi-asserted-by":"publisher","first-page":"114567","DOI":"10.1016\/j.socscimed.2021.114567","article-title":"Pharmaceutical messianism and the COVID-19 pandemic","volume":"292","author":"Lasco","year":"2022","journal-title":"Soc Sci Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.socscimed.2018.12.006","article-title":"Medical populism","volume":"221","author":"Lasco","year":"2019","journal-title":"Soc Sci Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e233257","DOI":"10.1001\/jamahealthforum.2023.3257","article-title":"Misinformation, trust, and use of invermectin and hydroxychloroquine for COVID-19","volume":"4","author":"Perlis","year":"2023","journal-title":"JAMA Health Forum"},{"key":"B11","doi-asserted-by":"publisher","first-page":"8342","DOI":"10.1002\/jcp.27725","article-title":"Medical cannabis: a plurimillennial history of an evergreen","volume":"234","author":"Pisnati","year":"2018","journal-title":"J Cell Physiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/AOG.0b013e318268049e","article-title":"Compounded bioidentical menopausal hormone therapy","volume":"120","year":"2012","journal-title":"Obstet Gynecol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of the North American menopause society","volume":"29","year":"2022","journal-title":"Menopause"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13697137.2024.2306272","article-title":"An ethical assessment of compounded bioidentical hormone therapy","author":"Kauffman","year":"2024","journal-title":"Climacteric"},{"key":"B15","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1097\/GCO.0b013e3283081ae9","article-title":"Bioidentical hormone therapy: a panacea that lacks supportive evidence","volume":"20","author":"Boothby","year":"2008","journal-title":"Curr Opin Obstet Gynecol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/sj.ijir.3901622","article-title":"Ethical problems with bioidentical hormone therapy","volume":"20","author":"Rosenthal","year":"2008","journal-title":"Int J Impot Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1097\/GME.0000000000000376","article-title":"What are the concerns about custom-compounded \u201cbioidentical\u201d hormone therapy?","volume":"21","author":"Pinkerton","year":"2014","journal-title":"Menopause"},{"key":"B18","volume-title":"Most Hospitals Obtain Compounded Drugs From Outsourcing Faciities Which Must Meet FDA Quality Standards","author":"Murrin","year":"2019"},{"key":"B19","article-title":"National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Committee on the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Replacement Therapy","volume-title":"The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use","author":"Jackson","year":"2020"},{"key":"B20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/GME.0000000000000523","article-title":"Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy","volume":"23","author":"Pinkerton","year":"2016","journal-title":"Menopause"},{"key":"B21","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1097\/GME.0000000000000196","article-title":"Risk of long-term hot flashes after natural menopause: evidence from the penn ovarian aging study cohort","volume":"21","author":"Freeman","year":"2014","journal-title":"Menopause"},{"key":"B22","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1001\/jamainternmed.2014.8063","article-title":"Duration of menopausal vasomotor symptoms over the menopause transition","volume":"175","author":"Avis","year":"2015","journal-title":"JAMA Intern Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women\u2019s health initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"B24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3109\/13697137.2012.660048","article-title":"Shock, terror and controversy: how the media reacted to the women\u2019s health initiative","volume":"15","author":"Brown","year":"2012","journal-title":"Climacteric"},{"key":"B25","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3109\/13697137.2012.655564","article-title":"Evidence-based assessment of the impact of the WHI on women\u2019s health","volume":"15","author":"Burger","year":"2012","journal-title":"Climacteric"},{"key":"B26","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1056\/NEJMcp1714787","article-title":"Hormone therapy for postmenopausal women","volume":"382","author":"Pinkerton","year":"2020","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1210\/endrev\/bnab011","article-title":"Hormone therapy in menopause: concepts, controversies, and approach to treatment","volume":"42","author":"Flores","year":"2021","journal-title":"Endocr Rev"},{"key":"B28","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jsbmb.2013.06.010","article-title":"Menopausal hormone therapy and breast cancer","volume":"142","author":"Santen","year":"2014","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/13697137.2017.1280251","article-title":"The evidence base for HRT: what can we believe?","volume":"20","author":"Langer","year":"2017","journal-title":"Climacteric"},{"key":"B30","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1089\/jwh.2005.14.592","article-title":"Postmenopausal hormone therapy and informed consent: a call for common sense","volume":"14","author":"Kauffman","year":"2005","journal-title":"J Womens Health"},{"key":"B31","volume-title":"Ageless: the Naked Truth About Bioidentical Hormones","author":"Somers","year":"2006"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1097\/GME.0000000000000901","article-title":"Promotion and marketing of bioidentical hormone therapy on the internet: a content analysis of websites","volume":"24","author":"Yuksel","year":"2017","journal-title":"Menopause"},{"key":"B33","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nrendo.2016.164","article-title":"Hormone-replacement therapy: current thinking","volume":"13","author":"Lobo","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"B34","author":"Seaborg","year":""},{"key":"B35","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1097\/GME.0000000000001356","article-title":"Determination of estradiol and progesterone content in capsules and creams from compounding pharmacies","volume":"26","author":"Stanczyk","year":"2019","journal-title":"Menopause"},{"key":"B36","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1331\/JAPhA.2014.14011","article-title":"How gaps in regulation of a compounding pharmacy set the stage for a multistate fungal meningitis outbreak","volume":"54","author":"Teshome","year":"2014","journal-title":"J Am Pharm Assoc"},{"key":"B37","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/13697137.2017.1285277","article-title":"Custom-compounded bioidentical hormone therapy: why so popular despite potential harm? The case against routine use","volume":"20","author":"L'Hermite","year":"2017","journal-title":"Climacteric"},{"key":"B38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.maturitas.2016.09.008","article-title":"Clinical audit of estradiol implant therapy: long duration of action and implications in non-hysterectomized women","volume":"94","author":"Wheatley","year":"2016","journal-title":"Maturitas"},{"key":"B39","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1097\/GME.0000000000001782","article-title":"Safety assessment of compounded non-FDA-approved hormonal therapy versus FDA-approved hormone therapy in treating menopausal women","volume":"29","author":"Jiang","year":"2021","journal-title":"Menopause"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e0197064","DOI":"10.1371\/journal.pone.0197064","article-title":"Conjugated equine estrogen and medroxyprogesterone acetate are associated with decreased risk of breast cancer relative to bioidentical hormone therapy and controls","volume":"13","author":"Zeng","year":"2018","journal-title":"PLoS One"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1210\/jc.2016-1271","article-title":"Compounded bioidentical hormones in endocrinology practice: an endocrine society scientific statement","volume":"101","author":"Santoro","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B42","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.socscimed.2015.02.027","article-title":"Bioidentical hormones, menopausal women, and the lure of the \u201cnatural\u201d in U.S. anti-aging medicine","volume":"132","author":"Fishman","year":"2015","journal-title":"Soc Sci Med"}],"container-title":["Frontiers in Reproductive Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frph.2024.1378644\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T04:50:48Z","timestamp":1709182248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frph.2024.1378644\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":42,"alternative-id":["10.3389\/frph.2024.1378644"],"URL":"https:\/\/doi.org\/10.3389\/frph.2024.1378644","relation":{},"ISSN":["2673-3153"],"issn-type":[{"value":"2673-3153","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]},"article-number":"1378644"}}